抗肿瘤抗生素与癌症靶向治疗  

Antitumor antibiotics and targeted cancer therapy

作　　者：甄永苏[1] 

机构地区：[1]中国医学科学院中国协和医科大学医药生物技术研究所,北京100050

出　　处：《中国抗生素杂志》2006年第2期65-68,共4页Chinese Journal of Antibiotics

摘　　要：抗肿瘤抗生素是微生物产生的活性物质。利用特定的模型和方法进行筛选或对已知化合物进行检测,已发现与报告对各种分子靶点显示高度活性的抗肿瘤抗生素。某些抗肿瘤抗生素如卡里奇霉素、力达霉素等对癌细胞有极强的杀伤作用,可以作为高效“弹头”药物,用于构建抗体靶向药物包括化学免疫偶联物和融合蛋白。抗肿瘤抗生素与抗体工程技术的结合可以作为新的技术平台,制备一系列的针对不同靶点的、用于治疗癌症的抗体靶向药物。Antitumor antibiotics are tumor-active substances produced by microorganisms. By screen ing or testing with particular assays, a number of antibiotics that display potent activity respectively to various molecular targets have been reported. Some antitumor antibiotics such as calicheamicin and lidamycin which exert extremely potent cytotoxicity to cancer cells can be used as potent ＂warhead＂ agent to constitute anti body-based drugs including chemoconjugates and fusion proteins. The integration of antitumor antibiotic and antibody engineering can serve as new technical platform for manufacture of a series of various target-specific ＇ antibody-based drugs for cancer therapy.

关 键 词：抗肿瘤抗生素 卡里奇霉索 力达霉紊 抗体靶向药物 

分 类 号：R979.14[医药卫生—药品]